Blue Cross Blue Shield · Berinert · US health-plan appeal rights

Berinert denied for failing step therapy by Blue Cross Blue Shield?

Q: How long do I have to appeal a Blue Cross Blue Shield Berinert denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Blue Cross Blue Shield typically requires

Blue Cross Blue Shield's specific coverage criteria for berinert are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: BCBS Berinert (pdC1-INH IV) On-Demand HAE Coverage

The Blue Cross Blue Shield angle on Berinert

## Why BCBS Applies Step Therapy to Berinert — and How to Challenge It

Step therapy (also called "fail-first") requires a patient to try one or more less-costly treatments before the plan will cover the requested drug. For Berinert, BCBS may require documentation that the patient tried an alternative HAE acute therapy first. These denials are frequently overturned when the treating specialist provides a well-structured letter explaining why the required step drug is clinically inappropriate or was already tried and failed.

## Why This Denial Is Appealable

Step-therapy protocols are designed for average populations, not for patients with documented clinical histories. If you previously tried the required alternative — or if your HAE specialist has a documented clinical reason why the alternative is contraindicated or unsuitable for you specifically — you likely qualify for a step-therapy exception. Many states have enacted step-therapy override laws that require insurers to grant exceptions when medical evidence supports the requested drug. Check whether your state's law applies to your plan type.

## Federal Appeal Framework

Internal appeal: File within the window shown on your denial notice. BCBS must issue a decision within 30 days (non-urgent) or 72 hours (urgent).
External review (ACA §2719): After exhausting internal appeals, request independent external review. The reviewer applies objective clinical standards, not plan-specific step-therapy protocols.
ERISA §503: Employer-plan members are entitled to full-and-fair review, including access to the clinical criteria underpinning the step-therapy requirement.
Expedited review: Available when delay would seriously jeopardize health; request explicitly in writing.
Four-month window: External review requests are generally due within four months of a final internal denial.

## Documentation to Gather

1. Prior-treatment records: Dated records showing every alternative HAE treatment tried, the doses used (from medical records, not self-reported), and the clinical outcomes. 2. Failure or contraindication documentation: If a required step drug failed, document the failure objectively (attack rate unchanged, adverse event, emergency visit). If it is contraindicated, the prescriber must state the clinical basis. 3. Specialist medical-necessity letter: Your HAE specialist should explain why Berinert is the appropriate therapy given the failed or unsuitable alternatives, citing current HAE management guidelines from the relevant professional organization (e.g., the US Hereditary Angioedema Association or comparable body) without quoting specific statistics. 4. FDA label for Berinert: Confirm that your intended use is within the approved indication. 5. BCBS step-therapy policy: Request the exact policy text so your appeal addresses each required step and exception criterion.

## Criteria-Mapping Structure

For each step listed in the BCBS policy, document: (1) the required alternative, (2) the date(s) it was tried or the clinical reason it was not tried, and (3) the outcome or basis for exception. Attach supporting chart notes for each entry. A table format makes it easy for the reviewer to verify compliance at a glance — and makes it harder to ignore.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Blue Cross Blue Shield appeals

Other denial reasons for Blue Cross Blue Shield Berinert

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.